Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GuideUpdated 7 min read

Tesamorelin prescription: who qualifies and how to get one

How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: you need a prescription for Egrifta WR, the only lawful tesamorelin product. If you are an adult with HIV and excess abdominal fat from lipodystrophy, a clinician can prescribe it for its labeled use. [1] Anyone else is looking at an off-label prescription for the same product, usually paid in cash. Compounded tesamorelin is not a lawful alternative: tesamorelin is a biologic. Egrifta moved to a biologics license (BLA 022505) on March 23, 2020, and FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin has no lawful basis. [5] [9] Research-labeled vials sold without a prescription are not lawful either.

That makes tesamorelin the one peptide in our catalog with a lawful prescription path today. This guide covers who qualifies, how off-label prescribing works, why compounding is off the table, what a legitimate telehealth visit should check, and what it costs. It does not give dosing advice; the FDA label dose is on the tesamorelin page.

Who qualifies for a tesamorelin prescription on label?

Egrifta WR is indicated for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. [1] The label sets three limits on that use: long-term cardiovascular safety has not been established, the drug is not indicated for weight loss because it is weight neutral, and there is no evidence it improves adherence to HIV medicines. [1]

The phase 3 trials that supported approval enrolled adults aged 18 to 65 on stable antiretroviral therapy with a large waist and a high waist to hip ratio, and excluded people with type 1 diabetes, diabetes treated with medication, a history of cancer, or pituitary disease. [1] In those trials, 26 weeks of treatment reduced visceral fat by 15.4% relative to placebo. [2]

The label also lists who should not take it at all: people with disruption of the hypothalamic pituitary axis (from pituitary surgery, tumors, head radiation, or head trauma), active malignancy, pregnancy, or known hypersensitivity to tesamorelin or its excipients. [1]

If this describes you, the usual route is your HIV clinician. Coverage generally follows the approved indication, so the HIV lipodystrophy page and the tesamorelin cost page are the places to start.

Can tesamorelin be prescribed off-label?

Most people searching "how to get tesamorelin" do not have HIV lipodystrophy. For them, the lawful route is an off-label prescription for Egrifta WR itself. A licensed clinician may prescribe an approved drug for a use not on its label, but insurance coverage generally follows the approved HIV indication, so off-label use is usually paid in cash.

Why can't a pharmacy compound tesamorelin?

Federal law lets a licensed 503A pharmacy compound a drug for an identified individual patient based on a valid prescription, using a drug substance that is a component of an FDA approved drug, among other conditions. [4] Tesamorelin does not qualify. It is a 44 amino acid protein, and on March 23, 2020 FDA deemed the Egrifta application (022505) to be a biologics license. [9] FDA states that biological products are not eligible for the 503A or 503B compounding exemptions. [5] The same transition is why compounded hCG stopped being lawful in 2020.

So compounded tesamorelin sold through telehealth programs or clinics has no lawful basis, whatever the price or packaging. Ipamorelin and CJC-1295 fail for a different reason: both were placed on FDA's Category 2 list in 2023 and their 503A nominations are now withdrawn, not on the 503A bulks list and not components of an approved drug. [6]

Two more things are worth knowing about off-label use:

  1. The use is off-label. No trial has tested tesamorelin for general fat loss, anti-aging, or muscle growth in healthy adults. The closest non-HIV evidence is one 12 month trial of 60 adults with abdominal obesity and reduced growth hormone secretion, which found less visceral fat and lower triglycerides than placebo. [3]
  2. Results depend on staying on it. In the approved trials, visceral fat returned after patients stopped. [2] See tesamorelin before and after for the full timeline.

Can you get a tesamorelin prescription online?

Yes, where state law allows a clinician to prescribe by telehealth. Search terms like "tesamorelin online" and "tesamorelin prescription online" mostly lead to telehealth programs that pair a visit with a compounding pharmacy, and compounded tesamorelin is not lawful. [5] A lawful telehealth visit ends in a prescription for Egrifta WR filled at a licensed pharmacy, with the same requirements as in person: a licensed prescriber, a real evaluation, and a valid prescription for you as an identified patient.

State rules on telehealth and compounding differ. Our legality hub collects the rules by state, and how to get peptides prescribed explains the general process for every peptide, including those with no approved or compounding route. For a plain definition of what clinics mean by the term, see what is peptide therapy.

What does a tesamorelin telehealth visit involve?

A legitimate visit should look like a medical evaluation, not a checkout page. The Egrifta WR label gives a good checklist of what a prescriber needs to know, even for off-label use:

  • Cancer history. Tesamorelin raises growth hormone, a known growth factor. The label says any prior malignancy should be inactive and its treatment complete before starting, and treatment should stop if cancer recurs. [1]
  • Glucose. Tesamorelin may cause glucose intolerance or diabetes, so the label calls for evaluating glucose before and during therapy. [1] Expect a baseline blood test.
  • IGF-1. The label recommends monitoring IGF-1 and considering stopping in patients with persistent elevations. After 26 weeks in the trials, 47% of patients had IGF-1 above 2 standard deviation scores. [1]
  • Pituitary disease and pregnancy. Both are contraindications, so a prescriber should ask. [1]
  • Side effects. Injection site reactions, fluid retention with joint pain or carpal tunnel symptoms, and hypersensitivity reactions are all label warnings. Injection site reactions affected 25% of patients versus 14% on placebo in the first 26 weeks. [1]
  • Sport. If you compete in a tested sport, say so. Tesamorelin is prohibited at all times under WADA section S2. [8]

A visit that asks none of these questions, skips labs, or sells a "protocol" before a clinician has seen you is a warning sign.

How much does tesamorelin cost?

Only one product is lawful, so the question is whether insurance covers it.

  • Egrifta WR. A published retail cash listing checked on September 22, 2026 put one 28 day kit at about 10,709 USD. [7] Insurance coverage generally applies to the approved HIV indication, so off-label use is usually paid at a cash price like this one.
  • Compounded tesamorelin. Telehealth and clinic prices far below the branded price are for a product with no lawful basis, because biologics are not eligible for the 503A or 503B compounding exemptions. [5] They are not a lawful alternative to Egrifta WR.

The tesamorelin cost page lists every channel with its checked date and source, and it is updated when prices change.

Where to get tesamorelin legally, and what to avoid

The lawful option is a prescription for Egrifta WR filled at a licensed pharmacy, for the approved use or off-label. [1] [9] PeptideAgent does not name or rank individual clinics, telehealth companies, or pharmacies.

Red flags that suggest a product is outside those channels:

  • It is sold without a prescription or a clinician visit.
  • It is labeled "research use only" or "not for human consumption."
  • It is compounded tesamorelin. Tesamorelin is a biologic, and biologics cannot be compounded under 503A. [5]
  • It is sold as a premixed blend with ipamorelin or CJC-1295. Neither ingredient can lawfully be compounded, and no trial has tested the combination. [6] See the tesamorelin and ipamorelin blend page.
  • It promises weight loss or muscle gain. The label describes a weight neutral drug, and no trial tested muscle growth. [1] See does tesamorelin build muscle.

Status changes, including the 2020 biologic transition, are logged on the tesamorelin regulatory tracker. To see how tesamorelin compares with the other fat-focused options, start with the fat loss and body composition page or the three-way tesamorelin vs sermorelin vs ipamorelin table. When a licensed provider directory is available, it will appear on our providers page.

What's actually offered, and what that means for you

Compounded tesamorelin is widely offered by clinics and telehealth prescribers. Tesamorelin is FDA approved, but FDA deemed its application (022505) a biologics license in March 2020, and biologics cannot be compounded under 503A or 503B. Compounded versions have no lawful basis. [1] [5] [9]

What that means for you

  • A pharmacy that compounds tesamorelin is taking a regulatory risk: biologics cannot be compounded under 503A or 503B. [5] [9]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [5]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [10]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [11] [12]

If you're going ahead anyway

Each step is on the tesamorelin page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make a compounded version lawful or safe; only the approved product is lawful. [9]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Do you need a prescription for tesamorelin?

Yes. Egrifta WR is a prescription drug, and it is the only lawful tesamorelin product. Tesamorelin became a biologic in 2020, and FDA states biological products are not eligible for the 503A or 503B compounding exemptions. [1] [5] [9]

Who qualifies for Egrifta on label?

Adults with HIV who have lipodystrophy with excess abdominal fat. Egrifta WR is not indicated for weight loss, and it is contraindicated with pituitary axis disorders, active cancer, pregnancy, and known hypersensitivity to tesamorelin or its excipients. [1]

Can you get tesamorelin online?

A licensed clinician can evaluate you by telehealth where state law allows and send a prescription for Egrifta WR to a licensed pharmacy. Compounded tesamorelin offered online has no lawful basis, because tesamorelin is a biologic and biologics are not eligible for the 503A or 503B compounding exemptions. [5] [9]

How much does Egrifta cost without insurance?

A published retail cash listing checked on 2026-09-22 put one 28 day kit of Egrifta WR at about 10,709 USD. Cash prices vary by pharmacy, and insurance coverage generally follows the approved HIV indication. [7]

Can athletes get a tesamorelin prescription?

A prescription does not change sport rules. Tesamorelin is prohibited at all times under WADA section S2, so a tested athlete with the approved condition would need a therapeutic use exemption. [8]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]FDA prescribing information for Egrifta WR (tesamorelin) for injection, revised March 2025, via DailyMed (Indications, Contraindications, Warnings, and Clinical Studies sections)FDA, 2025
  2. [2]Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010PubMed 20554713, 2010
  3. [3]Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 2012PubMed 23015655, 2012
  4. [4]FDA: Section 503A of the Federal Food, Drug, and Cosmetic Act (compounding for an identified individual patient on a valid prescription; components of approved drugs; essentially copies of commercially available drugs)FDA
  5. [5]FDA: Compounding and the FDA, questions and answersFDA
  6. [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA, 2026
  7. [7]Published retail cash price listing for tesamorelin (Egrifta WR) kits, accessed 2026-09-222026
  8. [8]WADA Prohibited List, section S2 (growth hormone releasing hormone and its analogues, including tesamorelin)WADA, 2026
  9. [9]FDA: List of approved NDAs for biological products that were deemed to be BLAs on March 23, 2020 (includes tesamorelin, Egrifta and Egrifta SV, application 022505)FDA, 2020
  10. [10]Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides (Mississippi Board of Nursing, Board of Pharmacy, State Board of Medical Licensure, August 19, 2026)2026
  11. [11]Louisiana Act No. 374 of 2026 (SB 253), enacting R.S. 37:23.52026
  12. [12]Louisiana Legislature: SB 253 (2026 Regular Session) bill history (signed May 22, 2026; effective August 1, 2026)2026

More from the blog